PEPG PepGen Inc.

BEARISH Impact: 7/10 EFFECT
Horizon weeks Filed May 22, 2026 Processed 18d 21h ago SEC 9999999995-26-001734
IPO/offering going effective
Latest settled — T+5d ⚠ clustered
PEPG ▼ -2.65% at T+5d
SHORT call ✓ call won +2.65% · α vs SPY +4.31% · entry $1.51 → $1.47
Next anchor: T+20d in 13d
Last close $1.35 (close Jun 8) · +10.60% from $1.51 entry (call sign-flipped)
Entry anchored
May 22, 2026
via day open
T+1d
+1.32%
call -1.32% · α -0.74%
$1.53
settled 15d ago
T+5d
-2.65%
call +2.65% · α +4.31%
$1.47
settled 9d ago
T+20d
call — · α —
in 13d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

PepGen's S-3 shelf registration (File No. 333-296016) became effective on May 21, 2026, enabling the company to sell up to $400M in securities including a $100M ATM facility. This follows a prior S-3 filing 3 days earlier and comes amid an unresolved FDA partial clinical hold on its lead DM1 candidate, with Q1 2026 cash of $132.3M sufficient into 2H 2027. The effectiveness creates immediate dilution overhang for existing shareholders.

Actionable Insight

The effective shelf creates immediate dilution risk. Monitor for ATM takedowns and any pricing announcements. The unresolved clinical hold adds binary risk — positive resolution could offset some dilution concerns, but the capital raise signal is clear. Consider positioning for continued weakness until the company provides clarity on clinical hold resolution and capital deployment plans.

Key Facts

  • S-3 shelf registration became effective on May 21, 2026
  • Shelf covers up to $400M in securities including a $100M ATM facility
  • Prior S-3 filed May 19, 2026 replaced an ATM with $88.5M remaining capacity
  • Q1 2026 net loss of $17.8M; cash of $132.3M sufficient into 2H 2027
  • Unresolved FDA partial clinical hold on lead DM1 candidate
  • Massive increase in authorized ATM capacity signals expected need for significant additional capital

Financial Impact

Up to $400M in potential dilution from shelf securities, with $100M ATM facility representing ~93% of current $107M market cap

dilutionshare countcash runway

Risk Factors

  • Immediate dilution overhang from $100M ATM facility
  • Unresolved FDA partial clinical hold on lead DM1 candidate
  • Cash runway only into 2H 2027 without additional capital
  • Historical model calls on PEPG have underperformed significantly (avg -61.66% at T+20)

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001734
Document: 9999999995-26-001734-index.html9999999995-26-001734
Document: 9999999995-26-001734.txt9999999995-26-001734
5 reports for PEPG
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for PEPG — sortable, filterable
Type Now
May 22, 2026
19d ago
EFFECT
BEARISH ★ 7/10
$1.51 $1.47▲ +2.65%▲ +4.31%$1.35 (+10.60%)
May 19, 2026
21d ago
S-3
BEARISH ★ 7/10
$1.38 $1.52▼ −10.14%▼ −7.90%$1.35 (+2.17%)
May 12, 2026
28d ago
8-K
NEUTRAL ★ 5/10
$1.78 $1.38▼ −22.47%▼ −21.31%$1.35 (−24.16%)
Mar 4, 2026
13w ago
8-K
MIXED ★ 6/10
$5.51 $6.15▲ +11.72%▲ +13.95%$1.35 (−75.48%)
Mar 4, 2026
14w ago
Insider Cluster
NEUTRAL ★ 3/10
$6.76 $6.29▼ −6.95%▼ −5.62%$1.35 (−80.03%)
Showing 5 of 5

US Market Status

Market Closed — Opens in 5h 50m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access